Ernexa Therapeutics

About Ernexa Therapeutics

Ernexa Therapeutics is dedicated to developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune diseases, aiming to transform treatments and deliver hope through cutting-edge cell therapy solutions.

Products & Services

ERNA-101:A lead cell therapy product designed to activate and regulate the immune system's response to target and attack cancer cells, specifically for ovarian cancer, using iMSCs as a delivery vehicle to infiltrate tumor tissue and trigger a strong immune response.

ERNA-102:A cell therapy product targeting inflammation to treat autoimmune diseases by calming overactive immune cells, promoting tissue repair, and offering a next-generation, tissue-targeted therapy with enhanced efficacy.

Specialties

Stem Cell Therapies Induced Pluripotent Stem Cells (iPSCs) Induced Mesenchymal Stem Cells (iMSCs) Cancer Treatment (Ovarian Cancer) Autoimmune Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Securities Purchase Agreement T: - FT: Securities Purchase Agreement	A: 6000000 MR: - FA: approximately $6.0 million FAN: 6000000	D: 2025-06-24 FD: 2025-06-24	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 7250000 MR: - FA: approximately $7,250,000 FAN: 7250000	D: 2025-04-03 FD: 2025-04-03	1 investors

Securities Purchase Agreement Latest

2025-06-24

$6.0M

1 investor (Pro only)

Private Placement 2025-04-03

$7.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News